Eledon Pharmaceuticals, Inc. (ELDN)

Market Cap	234.00M +2.8%
Revenue (ttm)	n/a
Net Income	-45.62M
EPS	-0.56
Shares Out	75.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,103,874
Open	2.980
Previous Close	2.880
Day's Range	2.942 - 3.165
52-Week Range	1.350 - 4.600
Beta	0.96
Analysts	Strong Buy
Price Target	8.50 (+175.53%)
Earnings Date	Mar 19, 2026

About ELDN

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney tran...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 33
• Stock Exchange: NASDAQ
• Ticker Symbol: ELDN
• Website: https://eledon.com

Analyst Summary

According to 2 analysts, the average rating for ELDN stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 175.53% from the latest price.

Price Target

$8.5

(175.53% upside)

Analyst Consensus: Strong Buy